Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

导出原文传递

翻译打印收藏纠错

第一作者： Sze-Wan,Li

第一单位： Campbell Family Institute for Breast Cancer Research, University Health Network, Princess Margaret Cancer Research Tower, MaRS Centre, 101 College Street, Toronto, Ontario MG5 1L7, Canada. Electronic address: swli@uhnresearch.ca.

作者： Sze-Wan,Li ^[1] ; Yong,Liu ^[2] ; Peter B,Sampson ^[2] ; Narendra Kumar,Patel ^[2] ; Bryan T,Forrest ^[2] ; Louise,Edwards ^[2] ; Radoslaw,Laufer ^[2] ; Miklos,Feher ^[2] ; Fuqiang,Ban ^[2] ; Donald E,Awrey ^[2] ; Richard,Hodgson ^[2] ; Irina,Beletskaya ^[2] ; Guodong,Mao ^[2] ; Jacqueline M,Mason ^[2] ; Xin,Wei ^[2] ; Xunyi,Luo ^[2] ; Reza,Kiarash ^[2] ; Erin,Green ^[2] ; Tak W,Mak ^[2] ; Guohua,Pan ^[2] ; Henry W,Pauls ^[3]

作者单位： Campbell Family Institute for Breast Cancer Research, University Health Network, Princess Margaret Cancer Research Tower, MaRS Centre, 101 College Street, Toronto, Ontario MG5 1L7, Canada. Electronic address: swli@uhnresearch.ca. ^[1] Campbell Family Institute for Breast Cancer Research, University Health Network, Princess Margaret Cancer Research Tower, MaRS Centre, 101 College Street, Toronto, Ontario MG5 1L7, Canada. ^[2] Campbell Family Institute for Breast Cancer Research, University Health Network, Princess Margaret Cancer Research Tower, MaRS Centre, 101 College Street, Toronto, Ontario MG5 1L7, Canada. Electronic address: henry.pauls@cogeco.ca. ^[3]

关键词 (1H-Indazol-6-yl)-methylene)indolin-2-ones Antitumor agent PLK4 inhibitors Polo-like kinase 4 Spiro[cyclopropane-1,3′-indolin]-2′-ones